中国生物工程杂志

［1］ Briggs J A, Wilk T, Fuller S D. Do lipid rafts mediate virus assembly and pseudotyping. J Gen Virol, 2003, 84(pt4): 757768. 
［2］ Sanders D A. No false start for novel pseudotyped vectors. Curr Opin Biotechnol, 2002, 13(5): 437442. 
［3］ Cohen J. Did Merck’s failed HIV vaccine cause harm? . Science, 2007, 318(5853): 10481049. 
［4］ Cohen J. Promising AIDS vaccine’s failure leaves field reeling. Science, 2007, 318(5847): 2829. 
［5］ Heyndrickx L, Vermoesen T, Vereecken K, et al. Antiviral compounds show enhanced activity in HIV1 single cycle pseudovirus assays as compared to classical PBMC assays. J Virol Methods, 2008, 148(12): 166173. 
［6］ 种辉辉, 许四宏, 王佑春. 评价HIV1抗病毒药物的重组假病毒法的建立及其初步应用. 药物分析杂志, 2008, 28(6):924927. Zhong H H, Xu S H, Wang Y C.Chin J Pharm Anal, 2008, 28(6): 924927. 
［7］ Adelson M E, Pacchia A L, Kaul M, et al. Toward the development of a viruscellbased assay for the discovery of novel compounds against human immunodeficiency virus type 1 . Antimicrob Agents Chemother, 2003, 47(2): 501508. 
［8］ Garcia J M, Gao A, He P L, et al. Highthroughput screening using pseudotyped lentiviral particles: A strategy for the identification of HIV1 inhibitors in a cellbased assay. Antiviral Res, 2009, 81(3): 239247. 
［9］ Wei X, Decker J M, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T20) monotherapy. Antimicrob Agents Chemother, 2002. 46(6): 18961905. 
［10］ Wei X, Decker J M, Wang S, et al. Antibody neutralization and escape by HIV1. Nature, 2003, 422(6929): 307312. 
［11］ He J, Choe S, Walker R, et a1. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol, 1995, 69(11): 67056711. 
［12］ 仇超, 彭虹,黄相刚等. 携带绿色荧光蛋白基因的单轮感染活性HIV假病毒的建立及其活性检测. 中华微生物学和免疫学杂志. 2006, 26(5): 394398. Qiu C, Peng H, Huang X G, et al.Chin J Microbiol Immunol, 2006, 26(5): 394398. 
［13］ 曹颖莉, 郭颖. 应用假病毒技术研究HIV1复制抑制剂. 药学学报, 2008, 43(3): 253258. Cao Y L, Guo Y.Acta Pharm Aceutica Sinica, 2008, 43(3): 253258. 
［14］ Mastromarino P, Conti C, Goldoni P, et al. Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J. Gen. Virol, 1987, 68(pt9): 23592369. 
［15］ Petropoulos C J, Parkin N T, Limoli K L, et a1. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2000, 44(4): 920928. 
［16］ Chan E, HeilekSnyder G, Cammack N, et al. Development of a Moloney murine leukemia virusbased pseudotype antiHIV assay suitable for accurate and rapid evaluation of HIV entry inhibitors. J Biomol Screen, 2006, 11(6): 652663. 
［17］ Lee M K, Seo J K, Kim H K, et a1.A vector system for introducing foreign HIV1 env genes and pseudotyping of MuLV particles with the recombinant HIV1 envelope proteins for antiHIV1 assay. Antiviral Res, 2002, 53(2):99111. 
［18］ Takeuchi Y, Simpson G, Vile R G,et al. Retroviral pseudotypes produced by rescue of a Moloney murine leukemia virus vector by Ctype, but not Dtype, retroviruses. Virology, 1992 , 186(2):792794. 
［19］ 苗文泉,李敬云.抗HIV药物的筛选评价方法. 国外医学药学分册, 2007, 34(3):170173. Miao W Q, Li J Y.Foreign Medical Sciences Section of Pharmacy, 2007, 34(3): 170173. 
［20］ Kageyama S, Kurokawa M, Shiraki K. Extract of prunella vulgaris spikes inhibits HIV replication at reverse transcription in vitro and can be absorbed from intestine in vivo. Antivir Chem Chemother,2000,11(2): 157164. 
［21］ Westby M, Nakayama G R, Butler S L, et al. Cellbased and biochemical screening approaches for the discovery of novel HIV1 inhibitors. Antiviral Res, 2005, 67(3): 121140. 
［22］ GarciaPerez J, SanchezPalomino S, PerezOlmeda M, et al. A new strategy based on recombinant viroses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.J Med Virol, 2007,79(2):127137. 
［23］ Stuyver L,Wyseur A, Rombout A, et a1. Line probe assay for rapid detection of drugselected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother, 1997, 41(2): 284291. 
［24］ Erali M, Page S, Reimer LG, et a1. Human immunodeficiency virus type 1 drug resistance testing: A comparison of three sequencebased methods. J Clin Microbiol, 2001, 39(6): 21572165. 
［25］ Iga M, Matsuda Z, Okayama A, et a1. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. J Virol Methods, 2002, 106(1): 2537. 
［26］ Race E, Dam E, Obry V, et a1. Analysis of HIV crossresistance to protease inhibitors using a rapid singlecycle recombinant virus assay for patients failing on combination therapies. AIDS, 1999, 13(15): 20612068. 
［27］ PerezElias M J, GarciaArota I, Munoz V, et al. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: A prospective, randomized study. Antivir Ther, 2003, 8(6): 577584. 
［28］ Japour A J, Mayers D L, Johnson V A, et a1. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother, 1993, 37(5):10951101. 
［29］ Paolucci S, Baldanti1 F, Zavattoni M, et al. Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV1 variants. J Antimicrob Chemother, 2004, 53(5): 766771.